Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells

• Published in: Journal of hematology and oncology Vol. 11; no. 1; pp. 92 - 13
• Main Authors: Han, Yali, Xie, Wei, Song, De-Gang, Powell, Daniel J.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.07.2018; BioMed Central; BMC
• Subjects: Adoptive transfer; Antigens; Antitumor agents; Breast cancer; Cancer therapies; Care and treatment; CD137 antigen; CD25 antigen; CD27 antigen; CD3 antigen; Chemotherapy; Chimeric antigen receptor; Chimeric antigen receptors; Experiments; Genetic aspects; Health aspects; Hematology; Immunotherapy; Interleukin 2; Ligands; Lymphocytes; Lymphocytes T; Microenvironments; NKG2D ligands; Oncology; Physiological aspects; T cell receptors; T cells; Triple-negative breast cancer; United States; Chimeric antigen receptor; T cells; NKG2D ligands; Immunotherapy; Triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive disease that currently lacks effective targeted therapy. NKG2D ligands (NKG2DLs) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy. We applied a chimeric...